Natera Inc. (NTRA)
NASDAQ: NTRAHealth CareMedical SpecialitiesUSD
At close: Oct 7, 4:00 PM ET · Delayed 15 min
After hours: 395.62 +0.02%
NTRA stock chart
Technical analysisKey statistics
All statistics- Market cap
- $57.02B
- EPS (TTM)
- -$1.35
- Dividend yield
- None
- 52-week range
- 167.99 – 437.41
- Day range
- 383.45 – 401.09
- Volume / Avg
- 2.82M / 1.42M
- Beta
- —
- Shares outstanding
- 144.14M
- Next earnings
- Nov 5, 2026
52-week range
NTRA stock today
Natera (NTRA) closed at $395.56 on Oct 7, down 1.27% (-$5.09), versus the S&P 500's 0.22% decline. Shares are 9.6% below their 52-week high of $437.41, set on Oct 6, 2026 and 135.5% above the 52-week low of $167.99, near the top of the past year's range. NTRA is up 75.0% year to date, outperforming the S&P 500 (+14.0%). Over the past 12 months, the stock has gained 137.9%.
Natera has posted a net loss over the last twelve months (EPS of -$1.35), so its P/E ratio is not meaningful. Natera's next earnings report is expected on Nov 5, 2026.
Summary generated from market data by MetaCap's automated system. Methodology
About Natera
Company profileNatera, Inc., a diagnostics company, engages in the development and commercialization of molecular testing services worldwide. It offers Signatera, a personalized ctDNA blood test for MRD assessment, early recurrence monitoring, and evaluation of treatment response in patients previously diagnosed with cancer; Latitude, a blood-based MRD test for colorectal cancer; Altera, a tissue based comprehensive genomic profiling test; and Empower, a hereditary cancer screening test. The company also provides Panorama, a non-invasive prenatal test; Horizon, a carrier screening test; Fetal Focus, a single-gene NIPT, or sgNIPT, that screens for 21 single-gene inherited conditions; and Vistara, a single-gene NIPT, which screens for 25 single-gene conditions.
- Sector
- Health Care
- Industry
- Medical Specialities
- CEO
- Mr. Steven Leonard Chapman
- Headquarters
- Austin, TX
- Employees
- 6,135
- IPO year
- 2015
- Website
- natera.com
Financial highlights
Full financialsIn fiscal 2025, Natera generated $2.31 billion in revenue, up 35.9% from fiscal 2024, its 8th consecutive year of revenue growth. Natera reported a net loss of $208.2 million, compared with a loss of $190.4 million a year earlier. Operating margin was -13.4%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $2.31B | $1.70B | $1.08B | $820.22M | $625.49M |
| Growth | +35.90% | +56.75% | +31.99% | +31.13% | +59.97% |
| Net income | $-208.16M | $-190.43M | $-434.80M | $-547.80M | $-471.72M |
| EPS (diluted) | $-1.52 | $-1.53 | $-3.78 | $-5.57 | $-5.21 |
Analyst forecast
ForecastConsensus (23 analysts)
strong_buy
Avg. price target
$377.43-4.58%
- Strong buy 5
- Buy 16
- Hold 2
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Next report
- Nov 5, 2026
- EPS estimate
- $-0.10
- Last reported (Q2 2026)
- Aug 7, 2026
- EPS actual vs est.
- $-0.47 vs —
NTRA news
All NTRA news- Natera: Priced To Perfection Amidst Rising Competitive ThreatsSeeking Alpha
- iShares Biotechnology ETF Experiences Big InflowNasdaqIBB, REGN, NTRA, ARGX
- Natera's Signatera Wins Japan PMDA Approval as Bladder Cancer CDxNasdaqNTRA, ISRG, GMED, VCYT
- Notable ETF Outflow Detected - XBI, TWST, HALO, NTRANasdaqXBI, TWST, HALO, NTRA
- Natera Announces Japan's PMDA Authorization For Signatera In Muscle-Invasive Bladder CancerNasdaq
- Natera, Inc. (NTRA) Presents at 2026 Global Healthcare Conference TranscriptSeeking Alpha
- Natera, Inc. (NTRA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptSeeking AlphaNTRA, MS
- Natera CEO Steven Chapman Sells 1,698 Shares for $545,000Nasdaq
Natera peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| HUMHumana Inc. | 396.51 | -1.92% | $47.61B | vs NTRA |
| CIThe Cigna Group | 278.51 | +1.51% | $73.59B | vs NTRA |
| ILMNIllumina Inc. | 267.76 | -2.11% | $40.43B | vs NTRA |
| CNCCentene Corporation | 64.99 | +0.59% | $32.10B | vs NTRA |
| ELVElevance Health Inc. | 404.31 | +1.05% | $87.68B | vs NTRA |
| LHLabcorp Holdings Inc. | 311.97 | +0.08% | $25.30B | vs NTRA |
| DGXQuest Diagnostics Incorporated | 227.06 | -0.58% | $25.06B | vs NTRA |
| GHGuardant Health Inc. | 168.33 | -1.38% | $22.59B | vs NTRA |
Indexes, lists and sector
Natera stock FAQ
What is Natera's stock price today?
NTRA last traded at $395.56 as of Oct 7, 4:00 PM EDT, down 1.27% on the day. Prices are delayed at least 15 minutes.
When is Natera's next earnings date?
Natera is expected to report earnings on Thursday, November 5, 2026. Analysts expect EPS of $-0.10.
Who is Natera's CEO?
Mr. Steven Leonard Chapman is the chief executive officer of Natera Inc., which has about 6,135 employees.
What is the NTRA 52-week high?
The 52-week high for NTRA is $437.41 and the 52-week low is $167.99. The stock is currently 9.6% below its high.